These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 29325448)

  • 1. Impact of CYP2C19 Genotype on Escitalopram Exposure and Therapeutic Failure: A Retrospective Study Based on 2,087 Patients.
    Jukić MM; Haslemo T; Molden E; Ingelman-Sundberg M
    Am J Psychiatry; 2018 May; 175(5):463-470. PubMed ID: 29325448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of age on serum concentrations of venlafaxine and escitalopram in different CYP2D6 and CYP2C19 genotype subgroups.
    Waade RB; Hermann M; Moe HL; Molden E
    Eur J Clin Pharmacol; 2014 Aug; 70(8):933-40. PubMed ID: 24858822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of cytochrome P450 2C19 polymorphisms on citalopram/escitalopram exposure: a systematic review and meta-analysis.
    Chang M; Tybring G; Dahl ML; Lindh JD
    Clin Pharmacokinet; 2014 Sep; 53(9):801-11. PubMed ID: 25154506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of CYP2C19 genotype on sertraline exposure in 1200 Scandinavian patients.
    Bråten LS; Haslemo T; Jukic MM; Ingelman-Sundberg M; Molden E; Kringen MK
    Neuropsychopharmacology; 2020 Feb; 45(3):570-576. PubMed ID: 31649299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Novel CYP2C-Haplotype Associated With Ultrarapid Metabolism of Escitalopram.
    Bråten LS; Haslemo T; Jukic MM; Ivanov M; Ingelman-Sundberg M; Molden E; Kringen MK
    Clin Pharmacol Ther; 2021 Sep; 110(3):786-793. PubMed ID: 33759177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of age, weight, and CYP2C19 genotype on escitalopram exposure.
    Jin Y; Pollock BG; Frank E; Cassano GB; Rucci P; Müller DJ; Kennedy JL; Forgione RN; Kirshner M; Kepple G; Fagiolini A; Kupfer DJ; Bies RR
    J Clin Pharmacol; 2010 Jan; 50(1):62-72. PubMed ID: 19841156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Cytochrome P450 (CYP) 2C19 Genotypes on Steady-State Plasma Concentrations of Escitalopram and its Desmethyl Metabolite in Japanese Patients With Depression.
    Tsuchimine S; Ochi S; Tajiri M; Suzuki Y; Sugawara N; Inoue Y; Yasui-Furukori N
    Ther Drug Monit; 2018 Jun; 40(3):356-361. PubMed ID: 29570504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP2C19 variation, not citalopram dose nor serum level, is associated with QTc prolongation.
    Kumar Y; Kung S; Shinozaki G
    J Psychopharmacol; 2014 Dec; 28(12):1143-8. PubMed ID: 25122046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients.
    Rudberg I; Mohebi B; Hermann M; Refsum H; Molden E
    Clin Pharmacol Ther; 2008 Feb; 83(2):322-7. PubMed ID: 17625515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Age of onset for increased dose-adjusted serum concentrations of antidepressants and association with sex and genotype: An observational study of 34,777 individuals.
    Tveit K; Hermann M; Nilsen RM; Wallerstedt SM; Rongve A; Molden E; Hole K
    Eur J Clin Pharmacol; 2024 Mar; 80(3):435-444. PubMed ID: 38197945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of
    Zastrozhin MS; Skryabin V; Rwere F; Petukhov AE; Pankratenko EP; Pozdniakov SA; Ivanchenko VA; Noskov VV; Zaytsev IA; Vinokurova NV; Horyaev DS; Vlasovskih RV; Bryun EA; Sychev DA
    Psychopharmacol Bull; 2022 Jun; 52(3):8-19. PubMed ID: 35815173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring the role of drug-metabolising enzymes in antidepressant side effects.
    Hodgson K; Tansey KE; Uher R; Dernovšek MZ; Mors O; Hauser J; Souery D; Maier W; Henigsberg N; Rietschel M; Placentino A; Craig IW; Aitchison KJ; Farmer AE; Dobson RJ; McGuffin P
    Psychopharmacology (Berl); 2015 Jul; 232(14):2609-17. PubMed ID: 25761838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic differences in cytochrome P450 enzymes and antidepressant treatment response.
    Hodgson K; Tansey K; Dernovsek MZ; Hauser J; Henigsberg N; Maier W; Mors O; Placentino A; Rietschel M; Souery D; Smith R; Craig IW; Farmer AE; Aitchison KJ; Belsey S; Davis OS; Uher R; McGuffin P
    J Psychopharmacol; 2014 Feb; 28(2):133-41. PubMed ID: 24257813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of Escitalopram Metabolic Ratios as Potential Biomarkers for Predicting CYP2C19 Poor Metabolizers.
    Faraj P; Hermansen A; Molden E; Hole K
    Ther Drug Monit; 2022 Dec; 44(6):720-728. PubMed ID: 36372933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of CYP2C19 polymorphisms on citalopram metabolism in patients with major depressive disorder.
    Uckun Z; Baskak B; Ozel-Kizil ET; Ozdemir H; Devrimci Ozguven H; Suzen HS
    J Clin Pharm Ther; 2015 Dec; 40(6):672-9. PubMed ID: 26343256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: Meta-analysis of data from genome-wide association studies.
    Fabbri C; Tansey KE; Perlis RH; Hauser J; Henigsberg N; Maier W; Mors O; Placentino A; Rietschel M; Souery D; Breen G; Curtis C; Lee SH; Newhouse S; Patel H; O'Donovan M; Lewis G; Jenkins G; Weinshilboum RM; Farmer A; Aitchison KJ; Craig I; McGuffin P; Schruers K; Biernacka JM; Uher R; Lewis CM
    Eur Neuropsychopharmacol; 2018 Aug; 28(8):945-954. PubMed ID: 30135031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of CYP2C19 Pharmacogenetic Testing on Predicting Citalopram and Escitalopram Tolerability and Efficacy: A Retrospective, Longitudinal Cohort Study.
    Mahajna M; Abu Fanne R; Berkovitch M; Tannous E; Vinker S; Green I; Matok I
    Biomedicines; 2023 Dec; 11(12):. PubMed ID: 38137466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined effect of CYP2C19 and CYP2D6 genotypes on escitalopram serum concentration and its metabolic ratio in a European patient population.
    Faraj P; Haslemo T; Tran JP; Stingl J; Molden E; Hole K
    Br J Clin Pharmacol; 2024 Oct; 90(10):2630-2637. PubMed ID: 38925553
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Baumel WT; Poweleit EA; Neptune Z; Schroeder HK; Ramsey LB; Mills J; Strawn JR
    J Child Adolesc Psychopharmacol; 2024 Feb; 34(1):67-69. PubMed ID: 38377524
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of CYP2C19 and CYP2D6 gene variants on escitalopram and aripiprazole treatment outcome and serum levels: results from the CAN-BIND 1 study.
    Islam F; Marshe VS; Magarbeh L; Frey BN; Milev RV; Soares CN; Parikh SV; Placenza F; Strother SC; Hassel S; Taylor VH; Leri F; Blier P; Uher R; Farzan F; Lam RW; Turecki G; Foster JA; Rotzinger S; Kennedy SH; Müller DJ
    Transl Psychiatry; 2022 Sep; 12(1):366. PubMed ID: 36068210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.